Educational evidence summaries. No dosing, sourcing, or treatment instructions.
The Endocrine Evidence Desk reviews GH, GHRH, IGF-1 and ghrelin-receptor mechanisms using primary research and regulatory sources.
54 published notesAn evidence-led Modified GRF (1-29) review focused on gh and igf-1 biomarkers, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led Modified GRF (1-29) review focused on receptor pathway map, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led Modified GRF (1-29) review focused on terminology audit, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 DAC review focused on healthy-aging claims, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 DAC review focused on adverse-event reporting, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 DAC review focused on sampling and assay timing, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 DAC review focused on human trial design, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 DAC review focused on pharmacokinetic interpretation, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 DAC review focused on gh and igf-1 biomarkers, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk